-
Surface Oncology Inc NASDAQ:SURF Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
Location: 50 Hampshire St Fl 8, Massachusetts, 02139-1548, US | Website: www.surfaceoncology.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.34%
Insider Ownership
7.28%
Institutional Own.
46.03%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SRF388 (IL-27) Details Solid tumor/s, Cancer | Phase 2 Update | |
SRF114 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
NZV930 (CD73) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
GSK4381562 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
SRF617 (CD39) Details Solid tumor/s, Cancer | Failed Discontinued |